US 2017/0304348 A1Published application

MiRNA and its Diagnostic and Therapeutic Uses in Diseases or Conditions Associated with Melanoma, or in Diseases or Conditions Associated with Activated BRAF Pathway

AssigneesInterna Technologies B.V., Koninklijke Nederlandse Akademie van Wetenschappen

InventorsEugene Berezikov, Jos Bernard Poell, Willemijn Maria Gommans, Rick Jan van Haastert, Andreas Alphons F.L. van Puijenbroek, Roeland Quirinus Jozef Schaapveld, Gregoire Pierre Andre Prevost

Life of this patent

Estimating the term…

Abstract

The invention relates to the diagnostic and therapeutic uses of a miRNA molecule, an equivalent or a source thereof in a disease and condition associated with melanoma or a disease or a condition associated with activated BRAF pathway.

Claims12

Dependent claims

A method for inhibiting growth and/or reducing viability of melanoma cells, said method comprising:

administering to said cells an effective amount of at least one miRNA molecule or a composition comprising an effective amount of said at least one miRNA molecule, wherein said at least one miRNA molecule is selected from the group consisting of:
a miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in seed sequence SEQ ID NO:172 and having at least 70% identity with SEQ ID NO:
11 (miRNA-203),
an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in a seed sequence selected from the group consisting of SEQ ID NOs:160 and 161 and having at least 70% identity with SEQ ID NO:99 or 100 (miRNA-10b),
an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in a seed sequence selected from the group consisting of SEQ ID NOs:162 and 163 and having at least 70% identity with SEQ ID NO:101 or 102 (miRNA-18b),
an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in seed sequence SEQ ID NO:166 and having at least 70% identity with SEQ ID NO:105 (miRNA-128),
an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in seed sequence SEQ ID NO:170 and having at least 70% identity with SEQ ID NO:109 (miRNA-184),
an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in seed sequence SEQ ID NO:171 and having at least 70% identity with SEQ ID NO:110 (miRNA-190b),
an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in seed sequence SEQ ID NO:173 and having at least 70% identity with SEQ ID NO:112 (miRNA-3157),
an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in seed sequence SEQ ID NO:177 and having at least 70% identity with SEQ ID NO:116 (miRNA-133a),
an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in a seed sequence selected from the group consisting of SEQ ID NOs:183 and 184 and having at least 70% identity with SEQ ID NO:122 or 123 (miRNA-200c),
an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in seed sequence SEQ ID NO:190 and having at least 70% identity with SEQ ID NO:129 (miRNA-610),
an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in seed sequence SEQ ID NO:185 and having at least 70% identity with SEQ ID NO:124 (miRNA-95),
an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in a seed sequence selected from the group consisting of SEQ ID NOs:188 and 189 and having at least 70% identity with SEQ ID NO:127 or 128 (miRNA-193a),
an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in a seed sequence selected from the group consisting of SEQ ID NOs:181 and 182 and having at least 70% identity with SEQ ID NO:120 or 121 (miRNA-497),
an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in a seed sequence selected from the group consisting of SEQ ID NOs:178, 179 and 180 and having at least 70% identity with SEQ ID NO:117, 118 or 119 (miRNA-509),
an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in a seed sequence selected from the group consisting of SEQ ID NOs:157, 158 and 159 and having at least 70% identity with SEQ ID NO:96, 97 or 98 (miRNA-7) and/or
a precursor of said miRNA molecule.

15 more elements

Dependencies are inferred from the claim text.

Facts

Application: 15/625,945Filed 16 Jun 2017
Priority: EP 10168592.36 Jul 2010
Published: 26 Oct 2017
Term ends: Not estimatedThe source records don’t support an estimate.

Classification15 codes

A61K 31/7088
Carbohydrates; Sugars; Derivatives thereof: compounds having three or more nucleosides or nucleotides
A61P 35/00
Antineoplastic agents
C12N 15/111
DNA or RNA fragments; Modified forms thereof ; Non-coding nucleic acids having a biological activity: general methods applicable to biologically…
C12N 15/113
DNA or RNA fragments; Modified forms thereof ; Non-coding nucleic acids having a biological activity: non-coding nucleic acids modulating the…

Family

Application61/361,787Us provisional application · filed 6 Jul 2010
Application13/734,414Continuation · filed 4 Jan 2013
Application15/625,945Continuation
US 10,583,149 B2Related patent
US 2013/0109741 A1Published application
US 9,682,095 B2Related patent
US 2017/0304348 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

MiRNA and its Diagnostic and Therapeutic Uses in Diseases or Conditions Associated with Melanoma, or in Diseases or Conditions Associated with Activated BRAF Pathway

AssigneesInterna Technologies B.V., Koninklijke Nederlandse Akademie van Wetenschappen

InventorsEugene Berezikov, Jos Bernard Poell, Willemijn Maria Gommans, Rick Jan van Haastert, Andreas Alphons F.L. van Puijenbroek, Roeland Quirinus Jozef Schaapveld, Gregoire Pierre Andre Prevost

Life of this patent

Estimating the term…

Abstract

A method for inhibiting growth and/or reducing viability of melanoma cells, said method comprising:

administering to said cells an effective amount of at least one miRNA molecule or a composition comprising an effective amount of said at least one miRNA molecule, wherein said at least one miRNA molecule is selected from the group consisting of:
a miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in seed sequence SEQ ID NO:172 and having at least 70% identity with SEQ ID NO:
11 (miRNA-203),
an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in a seed sequence selected from the group consisting of SEQ ID NOs:160 and 161 and having at least 70% identity with SEQ ID NO:99 or 100 (miRNA-10b),
an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in a seed sequence selected from the group consisting of SEQ ID NOs:162 and 163 and having at least 70% identity with SEQ ID NO:101 or 102 (miRNA-18b),
an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in seed sequence SEQ ID NO:166 and having at least 70% identity with SEQ ID NO:105 (miRNA-128),
an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in seed sequence SEQ ID NO:170 and having at least 70% identity with SEQ ID NO:109 (miRNA-184),
an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in seed sequence SEQ ID NO:171 and having at least 70% identity with SEQ ID NO:110 (miRNA-190b),
an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in seed sequence SEQ ID NO:173 and having at least 70% identity with SEQ ID NO:112 (miRNA-3157),
an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in seed sequence SEQ ID NO:177 and having at least 70% identity with SEQ ID NO:116 (miRNA-133a),
an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in a seed sequence selected from the group consisting of SEQ ID NOs:183 and 184 and having at least 70% identity with SEQ ID NO:122 or 123 (miRNA-200c),
an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in seed sequence SEQ ID NO:190 and having at least 70% identity with SEQ ID NO:129 (miRNA-610),
an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in seed sequence SEQ ID NO:185 and having at least 70% identity with SEQ ID NO:124 (miRNA-95),
an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in a seed sequence selected from the group consisting of SEQ ID NOs:188 and 189 and having at least 70% identity with SEQ ID NO:127 or 128 (miRNA-193a),
an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in a seed sequence selected from the group consisting of SEQ ID NOs:181 and 182 and having at least 70% identity with SEQ ID NO:120 or 121 (miRNA-497),
an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in a seed sequence selected from the group consisting of SEQ ID NOs:178, 179 and 180 and having at least 70% identity with SEQ ID NO:117, 118 or 119 (miRNA-509),
an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in a seed sequence selected from the group consisting of SEQ ID NOs:157, 158 and 159 and having at least 70% identity with SEQ ID NO:96, 97 or 98 (miRNA-7) and/or
a precursor of said miRNA molecule.

15 more elements

Facts

Application

15/625,945Filed 16 Jun 2017

Priority

EP 10168592.36 Jul 2010

Published

26 Oct 2017

Term ends

Not estimatedThe source records don’t support an estimate.

Classification15 codes

A61K 31/7088
Carbohydrates; Sugars; Derivatives thereof: compounds having three or more nucleosides or nucleotides
A61P 35/00
Antineoplastic agents
C12N 15/111
DNA or RNA fragments; Modified forms thereof ; Non-coding nucleic acids having a biological activity: general methods applicable to biologically…
C12N 15/113
DNA or RNA fragments; Modified forms thereof ; Non-coding nucleic acids having a biological activity: non-coding nucleic acids modulating the…

Family

Application61/361,787Us provisional application · filed 6 Jul 2010

Application13/734,414Continuation · filed 4 Jan 2013

Application15/625,945Continuation

US 10,583,149 B2Related patent

US 2013/0109741 A1Published application

US 9,682,095 B2Related patent

US 2017/0304348 A1This patent

From the US filing history. Foreign family members aren’t listed.